Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials

Thomas Lodise; Sam Colman; Daniel S Stein; David Fitts; Lisa Goldberg; Elizabeth Alexander; Patrick J Scoble; Jennifer Schranz

doi:10.1093/ofid/ofaa145

Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials

Open Forum Infect Dis. 2020 Apr 24;7(5):ofaa145. doi: 10.1093/ofid/ofaa145. eCollection 2020 May.

Authors

Thomas Lodise¹, Sam Colman², Daniel S Stein³, David Fitts³, Lisa Goldberg³, Elizabeth Alexander³, Patrick J Scoble³, Jennifer Schranz³

Affiliations

¹ Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
² Covance Market Access Services Inc., Gaithersburg, Maryland, USA.
³ Nabriva Therapeutics US, Inc., King of Prussia, Pennsylvania, USA.

Abstract

Time to clinical response, a proxy for hospital "discharge readiness," was compared between CABP inpatients who received lefamulin or moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP) trials. The analysis included 926 inpatients. A short and comparable median time to clinical response (4 days) was observed in both treatment groups.

Keywords: community-acquired bacterial pneumonia; fluoroquinolones; lefamulin; patient discharge; time to clinical response.